Optimising the evaluation of therapeutic response to first-line treatment of diffuse large B cell lymphoma Ahead of print

  • [1] Cheson B.D., Fisher R.I., Barrington S.F. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059-3068. 27
  • [2] Moskowitz C.H., Schoder H., Teruya-Feldstein J. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:1896-1903. 11
  • [3] Lin C., Itti E., Haioun C. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment visual analysis. J Nucl Med. 2007;48:1626-1632. versus10
  • [4] Itti E., Lin C., Dupuis J. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527-533. 4
  • [5] Meignan M., Gallamini A., Meignan M., Gallamini A., Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50:1257-1260. 8
  • [6] Toledano M.N., Vera P., Tilly H., Jardin F., Becker S. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: prognostic impact of tumor/liver ratio. PLoS One. 2019;14:e0211649. 2
  • [7] Zhang Y., Fan Y., Ying Z. Can the SUVmax-liver-based interpretation improve prognostic accuracy of interim and posttreatment 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma? Leuk Lymphoma. 2018;59:660-669. 3
  • [8] Itti E., Juweid M.E., Haioun C. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med. 2010;51:1857-1862. 12
  • [9] Le Gouill S., Casasnovas R.O. Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver? Blood. 2017;129:3059-3070. 23
  • [10] Eertink J.J., Burggraaff C.N., Heymans M.W. The optimal timing of interim 18F-FDG PET in diffuse large B-cell lymphoma: an individual patient data meta-analysis by the Petra Consortium. Blood. 2019;134:487. Supplement_1
  • [11] Casasnovas R.O., Ysebaert L., Thieblemont C. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood. 2017;130:1315-1326. 11
  • [12] Lamy T., Damaj G., Soubeyran P. R-CHOP 14 with or without radiotherapy in non bulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131:174-181. 2
  • [13] Freeman C.L., Savage K.J., Villa D. Long-term results of PET-guided radiation in advanced-stage diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 2021;137:929-938. 7
  • [14] Dührsen U., Müller S., Hertenstein B. Positron emission tomography–guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024-2034. 20
  • [15] Hüttmann A., Rekowski J., Müller S.P. Six eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial. Ann Hematol. 2019;98:897-907. versus4
  • [16] Arzuaga-Mendez J., Prieto-Fernandez E., Lopez-Lopez E., Martin-Guerrero I., Garcia-Ruiz J.C., Garcia-Orad A. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: a systematic review. Crit Rev Oncol Hematol. 2019;139:7-15.
  • [17] Camus V., Jardin F. Cell-free DNA and the monitoring of lymphoma treatment. Pharmacogenomics. 2019;20:1271-1282. 18
  • [18] Camus V., Sarafan-Vasseur N., Bohers E. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57:2171-2179. 9
  • [19] Bohers E., Viailly P.J., Becker S. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. Blood Cancer J. 2018;8:74. 8
  • [20] Roschewski M., Dunleavy K., Pittaluga S. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16:541-549. 5
  • [21] Scherer F., Kurtz D.M., Newman A.M. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8:364ra155. 364
  • [22] Kurtz D.M., Scherer F., Jin M.C. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36:2845-2853. 28
  • [23] Kurtz D.M., Esfahani M.S., Scherer F. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell. 2019;178:699-713e19. 3
  • [24] Cottereau A.S., Lanic H., Mareschal S. Molecular profile and FDG-PET metabolic volume at staging in DLBCL-response. Clin Cancer Res. 2016;22:3414-3415. 13
  • [25] Toledano M.N., Desbordes P., Banjar A. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45:680-688. 5